Author's response to reviews

Title: Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: A single-institution experience

Authors:

Takuya Koie (goodwin@cc.hirosaki-u.ac.jp)
Chikara Ohyama (coyama@cc.hirosaki-u.ac.jp)
Takahiro Yoneyama (uroyone@cc.hirosaki-u.ac.jp)
Hayato Yamamoto (ha-yama@cc.hirosaki-u.ac.jp)
Atsushi Imai (tsushi.imai@gmail.com)
Shingo Hatakeyama (shingorilla2@gmail.com)
Yasuhiro Hashimoto (y-hash@cc.hirosaki-u.ac.jp)
Tohru Yoneyama (tohruyon@cc.hirosaki-u.ac.jp)
Yuki Tobisawa (tobisawa@cc.hirosaki-u.ac.jp)
Kazuyuki Mori (moribio@cc.hirosaki-u.ac.jp)

Version: 2
Date: 30 September 2014

Author's response to reviews: see over
September 29, 2014

Dear Editor-in-Chief, the BMC Urology

We are sending herewith an original of our manuscript entitled “Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: A single-institution experience in Japan”. The paper is submitted to be considered for publication in the BMC Urology. We believe it contains important information about the feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma will be interest and value to the readers of the Journal.

The manuscript has not been published elsewhere and is not been considered concurrently by another publication. All of the authors have made a substantial contribution to the information submitted. Further, the authors are aware of and agree to the content of the manuscript and their being listed as an author on the paper. We have no commercial and financial incentive associated with publishing the manuscript.

Your consideration for this manuscript is greatly appreciated.

Sincerely yours,

Takuya Koie, M.D.
Associate Professor
Department of Urology, Hirosaki University Graduate School of Medicine,
5 Zaifucho, Hirosaki 036-8562, Japan
Fax: +81-172-39-5091, Tel: +81-172-39-5092
E-mail: goodwin@cc.hirosaki-u.ac.jp